What should personalized, precision treatment of cancer look like in the future?
We know that people are different, their tumors are different, and they respond differently to different therapies. Medical teams of the future might be able to create a ?“virtual twin” of a person and their tumor. Then, by tapping supercomputers, physician-led teams could simulate how tumor cells behave to test millions (or billions) of possible treatment combinations. Ultimately, the best combinations might offer clues towards a personalized, effective treatment plan.
Sound like wishful thinking? The first steps towards this vision have been undertaken by a multi-institution research collaboration that includes Jonathan Ozik and Nicholson Collier, computational scientists at the U.S. Department of Energy’s Argonne National Laboratory.
The research team, which includes collaborators at Indiana University and the University of Vermont Medical Center, brought the power of high-performance computing to the thorny challenge of improving cancer immunotherapy. The team tapped twin supercomputers at Argonne and the University of Chicago, finding that high-performance computing can yield clues in fighting cancer, as discussed in a June 7 article published in Molecular Systems Design and Engineering.
“With this new approach, researchers can use agent-based modeling in more scientifically robust ways.” — Nicholson Collier, computational scientist at Argonne and the University of Chicago
Standing up to cancer
Cancer immunotherapy is a promising treatment that realigns your immune system to reduce or eliminate cancer cells. The therapy, however, helps only 10 to 20 percent of patients — partly because the way in which cancer cells and immune cells mingle is complex and poorly understood. Proven rules are scarce.
To begin uncovering the rules of immunotherapy, the team turned to a set of three tools:
- Agent-based modeling, which predicted the behavior of individual ?“agents” – cancer and immune cells, in this case
- Argonne’s award-winning workflow technology to take full advantage of the supercomputers
- A guiding framework to explore models and dynamically direct and track results
The trio operate in a hierarchy. The framework, developed by Ozik, Collier, Argonne colleagues, and Gary An, a surgeon and professor at the University of Vermont Medical Center, is called Extreme-scale Model Exploration with Swift (EMEWS). It oversees the agent-based model and the workflow system, the Swift/T parallel scripting language, developed at Argonne and the University of Chicago.
What is unique about this combination of tools? ?“We are helping more people in a variety of computational science fields to do large-scale experimentation with their models,” said Ozik, who — like Collier — holds a joint appointment at the University of Chicago. ?“Building a model is fun. But without supercomputers, it is difficult to really understand the full potential of how models can behave.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Canceron November 18, 2019 at 4:08 pm
“We believe that this clinical collaboration has the potential to help us accelerate and deliver on the long-awaited promise of personalized medicine for these deserving patients.” Both companies will ...
- BRIEF—CarThera and Kiyatec collaborate on personalized medicine for glioblastomaon November 18, 2019 at 9:23 am
US biotech Kiyatec and France’s CarThera have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly ...
- Personalized Medicine Market By Product, Geography and Forecast 2019 – 2026on November 13, 2019 at 2:34 am
Nov 13, 2019 (Market Prediction via COMTEX) -- Acumen Research and Consulting has announced the addition of the “Personalized Medicine Market” report to their offering. The Personalized Medicine ...
- Global Personalized Medicine Market Advancement, Size, Growth, Access and Forecast 2019-2025 | Key Players – Abbott, Amgen, Astellas Pharma and Moreon November 13, 2019 at 1:48 am
QY Research offers an overarching research and analysis-based study on the global Personalized Medicine market, covering growth prospects, market development potential, profitability, supply and ...
- Personalized Medicine Market Comprehensive Insights Of Recent Developmentson November 11, 2019 at 10:42 pm
The report is readily available and can be dispatched immediately after payment confirmation.
- Interview with Wei Jian Goh of Craft Health on Personalized Medicine and Nutritionon November 8, 2019 at 12:16 am
Wei Jian Goh’s startup Craft Health makes personalized medicine and nutrition possible. The startup is one I’m very envious of as I’ve had a lot of ideas in this area for years. Ideas are nothing ...
- Cell Analysis Market - Global Forecast to 2024: Applications of Cell Analysis in Personalized Medicine Provides Lucrative Opportunitieson November 7, 2019 at 4:29 pm
DUBLIN, Nov. 7, 2019 /PRNewswire/ -- The "Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal ...
- Personalized Medicine Market Market Drivers 2019 - Industry Analysis, Regional Outlook and Segmented Analysis 2026on November 6, 2019 at 7:46 am
Nov 06, 2019 (Market Insight Reports via COMTEX) -- VMR has recently announced the addition of a new research report, titled 'Personalized Medicine Market Report 2019', offers a clear understanding of ...
- Consumer Familiarity, Perspectives and Expected Value of Personalized Medicine With a Focus on Applications in Oncologyon November 4, 2019 at 4:00 pm
Overall, among US consumers there was a lack of familiarity with personalized medicine. However, when provided definitions, respondents were optimistic about the prospect of personalized medicine ...
- Will Personalized Medicine Help in 'Transforming' the Business of Healthcare?on October 25, 2019 at 5:00 pm
I mentioned at the beginning of this perspective that I did not find the present direction/definition for personalized medicine optimal. I will now present my personal preference of the direction that ...
via Bing News